Position in LPCN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,356,962
New position
Shares Held
294,989
first reported quarter
Ownership
3.58%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Eversept Partners, LP holds $675,198,480 across 57 Biotechnology names. LPCN ranks #36 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
934,423 | $104,048,001 | |
| 2 | VERA |
Vera Therapeutics, Inc.
|
2,173,286 | $87,431,295 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
2,885,622 | $67,408,129 | |
| 4 | CLDX |
Celldex Therapeutics, Inc.
|
1,788,016 | $56,715,867 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
924,193 | $53,704,855 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
632,100 | $47,464,389 | |
| 7 | GERN |
Geron Corp
|
18,834,883 | $28,063,975 | |
| 8 | TVTX |
Travere Therapeutics, Inc.
|
542,610 | $16,120,943 |
All Filings in LPCN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,356,962 | 294,989 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||